Syt11 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SYT11 (Synaptotagmin-11) is a synaptic protein that plays a critical role in neurodegenerative disease, particularly Parkinson's disease. It is located on chromosome 1q41 and catalogued as NCBI Gene ID 23475.
SYT11 is a member of the synaptotagmin family but uniquely lacks Ca2+-binding domains, distinguishing it from other synaptotagmin proteins that function as calcium sensors for synaptic vesicle exocytosis [Citation 1]. Despite lacking calcium-binding capability, SYT11 has emerged as an important regulator of synaptic function and autophagy in dopaminergic neurons, with reduced expression strongly implicated in Parkinson's disease pathogenesis [Citation 2].
SYT11 contains a distinctive domain architecture that differentiates it from calcium-sensing synaptotagmins:
| Attribute | Value |
|---|---|
| Protein Name | Synaptotagmin 11 |
| Gene Symbol | SYT11 |
| Chromosome | 1q41 |
| UniProt | Q9BT88 |
| Molecular Weight | 47 kDa |
| Amino Acids | 421 |
| Subcellular Localization | Synaptic vesicles, Cytoplasm |
| Protein Family | Synaptotagmin family |
SYT11 possesses:
The loss of canonical calcium-binding residues in both C2 domains classifies SYT11 as a "synaptotagmin-like" protein that functions independently of calcium influx [Citation 3].
SYT11 is involved in synaptic vesicle trafficking and may regulate neurotransmitter release through:
SYT11 interacts with the autophagy machinery through:
This autophagy-regulating function is particularly important in dopaminergic neurons, which are highly vulnerable in Parkinson's disease [Citation 5].
SYT11 is expressed throughout the brain with highest levels in:
The high expression in PD-vulnerable regions suggests a region-specific vulnerability mechanism [Citation 6].
SYT11 has emerged as a significant PD risk gene and therapeutic target:
Genetic Evidence:
Pathogenic Mechanisms:
α-Synuclein Connection:
Alzheimer's Disease:
Amyotrophic Lateral Sclerosis (ALS):
No FDA-approved therapies directly targeting SYT11 exist, but several approaches are under investigation:
SYT11 expression in:
SYT11 interacts with several proteins relevant to neurodegeneration:
| Partner | Interaction Type | Function |
|---|---|---|
| VAMP2 | SNARE complex | Synaptic vesicle fusion |
| SNAP25 | SNARE complex | Presynaptic release |
| PI3K (Vps34) | Regulatory | Autophagy initiation |
| ATG14L | Autophagy | Autophagosome formation |
| LAMP2 | Lysosomal | Autophagosome-lysosome fusion |
| α-Synuclein | Functional | Synaptic vesicle regulation |
Page updated: 2026-03-07
The study of Syt11 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.